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We review recent findings pertaining to several environmental agents (ethanol, phencyclidine,
ketamine, nitrous oxide, barbiturates, benzodiazepines, halothane, isoflurane, and propofol) that
have the potential to delete large numbers of neurons from the developing brain by a newly
discovered mechanism involving interference in the action of neurotransmitters [glutamate and
y-amino butyric acid (GABA) at Nmethyl-D-aspartate (NMDA)1 and GABAA receptors during the
synaptogenesis period, also known as the brain growth-spurt period. Transient interference (lasting
> 4 hr) in the activity of these transmitters during the synaptogenesis period (the last trimester of
pregnancy and the first several years after birth in humans) causes millions of developing neurons
to commit suicide (die by apoptosis). Many of these agents are drugs of abuse (ethanol is a prime
example) to which the human fetal brain may be exposed during the third trimester by drug-abusing
mothers. Ethanol triggers massive apoptotic neurodegeneration in the developing brain by
interfering with both the NMDA and GABAA receptor systems, and this can explain the reduced
brain mass and lifelong neurobehavioral disturbances associated with intrauterine exposure of the
human fetus to ethanol (fetal alcohol syndrome). Exposure of the immature brain in a medical
treatment context is also of concern because many of these agents are drugs used frequently as
sedatives, tranquilizers, anticonvulsants, or anesthetics in pediatric and/or obstetrical medicine.
Because this is a newly discovered mechanism, further research will be required to fully ascertain
the nature and degree of risk posed by exposure of the developing human brain to environmental
agents that act by this mechanism. Key words: anesthetics, apoptosis, barbiturates,
benzodiazepines, ethanol, GABAA receptors, ketamine, NMDA receptors, phencyclidine,
synaptogenesis. - Environ Health Perspect 108(suppl 3):383-388 (2000).
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We are exploring mechanisms by which
environmental agents can disrupt develop-
ment of the brain, thereby giving rise to
neurobehavioral disturbances that may be
expressed either in childhood or with
delayed onset in adulthood. Our interest in
this topic was originally prompted by the
discovery (1) three decades ago that gluta-
mate (Glu), a widely used food additive,
destroys neurons in the developing brain.
Either oral or subcutaneous administration
ofGlu to infant animals (mice, rats, rabbits,
guinea pigs, and monkeys) at doses that
cause no obvious discomfort or disruption of
normal behaviors, such as suckling, quietly
destroys many neurons in the developing
hypothalamus. Although this pathological
event in the brain produces no overt signs of
dysfunction during infancy, as the animals
became adolescents they begin to display an
abnormal body habitus (short and fat), and
develop various disturbances in neuroen-
docrine function, including hypogonadism,
infertility, and reduced pituitary gland size.
The explanation for these abnormalities is
that the hypothalamic neurons deleted dur-
ing infancy perform important neuroen-
docrine regulatory functions pertaining to
aspects ofgrowth and development, includ-
ing reproductive capacity, that mature and
become functional in adolescence and early
adulthood (2). If Glu can induce lesions in
the developing brain that remain silent until
adolescence or early adulthood, other envi-
ronmental agents may also be able to inflict
silent damage on the developing brain; this
damage may not be expressed as a functional
abnormality until a later stage in ontogene-
sis, when the damaged brain circuitry fails to
mature and assume its adult functions.
Our search for other environmental
agents and other mechanisms that can subtly
disrupt normal brain development and give
rise to late onset neuropsychiatric distur-
bances has been fruitful. In this paper we
review some ofthe more interesting results of
this search.
Historical Perspective
The original observation that exogenous Glu
damages the developing brain by exciting
neurons to death (1) spawned a new field of
research called excitotoxicology. A series of
new findings in this field (3-5) led to the
realization that endogenous Glu, by an exci-
totoxic mechanism, plays a major role in trig-
gering neuronal degeneration in many if not
all acute brain injury syndromes [e.g., stroke,
perinatal asphyxia (hypoxia/ischemia),
epilepsy, hypoglycemia, and head and spinal
cord trauma]. This suggests the possibility
that something as simple as compression of
the umbilical cord causing transient ischemia
of the fetal brain could trigger excessive
release of endogenous Glu and excitotoxic
degeneration oflarge numbers ofdeveloping
neurons. Although this is of considerable
interest relative to the potential origins of
neurodevelopmental disabilities, it is not an
environmental mechanism. However, drugs
that were developed as antiexcitotoxic neu-
roprotective agents fit broadly into the cate-
gory of environmental agents, and some of
these agents had interesting neurotoxic side
effects. Examining the neurotoxic side
effects of drugs that were developed as
antagonists of N-methyl-D-aspartate
(NMDA) Glu receptors provides a good
starting point for our review.
NMDA Antagonist
Neurotoxicity in the
Adult Brain
Research pertaining to the neurotoxicity of
NMDA antagonists dates back 10 years to
the discovery (6) that systemic administra-
tion ofdrugs that block NMDA Glu recep-
tors causes acute pathomorphological
changes in cerebrocortical neurons of the
adult rat brain. Low doses ofNMDA antag-
onists, such as MK801 and phencyclidine
(PCP), produced reversible pathomorpho-
logical changes in cerebrocortical neurons,
whereas higher doses ofthese agents induced
irreversible neuronal degeneration that ini-
tially was thought to be limited to the poste-
rior cingulate and retrosplenial cortices
(6,7). However, more recent findings docu-
ment that high doses of these agents cause
irreversible degeneration ofneurons not only
in the cingulate and retrosplenial cortices
but in a number ofother corticolimbic brain
regions (8-11).
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ReceptorMechanisms andNeurl
CircuitryThatMediate NMDA
AntagonistNeurotoxicity
Early studies (12) showed that co-administra-
tion ofcertain commonly used drugs (benzo-
diazepines and barbiturates) that promote
7y-amino butyric acid (GABA)A transmission
block the neurotoxic effects ofNMDA antag-
onists. Subsequent studies (13,14) showed
that clinically relevant doses of GABAergic
drugs (halothane, isoflurane, and propofol)
that are used as general anesthetics also pre-
vent NMDA antagonist neurotoxicity. In a
series of additional studies (15-19), many
compounds were tested by systemic adminis-
tration. A surprisingly large number ofdiffer-
ent categories ofagents that interact selectively
with specific transmitter systems dose depen-
dently prevented the neurotoxic action ofthe
potent NMDA antagonist, MK801, on cere-
brocortical neurons. Neuroprotection was
demonstrated by all agents falling within the
following categories: muscarinic cholinergic
antagonists, non-NMDA glutamatergic antag-
onists, sigma receptor antagonists, GABAA
agonists, aX2-adrenergic agonists, and 5HT2A
serotonergic agonists. The neuroprotective
action was highlyreceptorspecific in that many
agents that act at other receptor subtypes or
other transmitter receptor systems were tested
and had no effecton MK801 neurotoxicity.
Based on the pharmacological evidence
generated thus far, we derived a circuit dia-
gram (Figure 1) that provides a relatively par-
simonious explanation for the cerebrocortical
neurotoxic action of systemically adminis-
tered NMDA antagonists. According to this
explanation, the mechanism is indirect and
involves the blockade ofNMDA receptors on
inhibitory neurons (GABAergic and noradren-
ergic) through which Glu normally maintains
tonic inhibitory control over major excitatory
pathways (both glutamatergic and cholinergic).
These pathways convergently feed into the
cerebral cortex from distant sites such as the
anterior thalamus (glutamatergic) and basal
forebrain (cholinergic). NMDA receptor
blockade inactivates the inhibitory neurons,
thereby disinhibiting the excitatory pathways,
causing them to excessively stimulate cerebro-
cortical neurons as the proximal mechanism
that mediates neuronal injury. In microdialysis
studies we (20) and others (21-2) confirmed
that systemic administration ofan NMDA
antagonist to the adult rat triggers abnormal
Figure 1. Proposed circuitry to explain how hypofunction of the NMDA receptor system can induce dysfunction and
injury of neurons in the PC/RSC by a disinhibition principle. Abbreviations: +, excitatory input; -, inhibitory input; ACh,
acetylcholine; GA, GABAA subtype of GABA receptor; 5HT, serotonin; 5HT2A, 5HT2A subtype of serotonergic receptor;
M3, M3 subtype of muscarinic cholinergic receptor; NE, norepinephrine; NMDA, NMDA subtype of Glu receptor;
PC/RSC, posterior cingulate/retrosplenial cortex; 6, sigma receptor; X2, X2 subtype of adrenergic receptor. Glu acting
at NMDA receptors on GABA, NE, and 5HT neurons maintains tonic inhibition over two excitatory inputs to the
PC/RSC neuron. Both excitatory inputs are subject to disinhibition when NMDA receptors are blocked. In addition, the
PC/RSC neuron uses Glu as a transmitter and gives off a recurrent collateral that terminates at an NMDA receptor on
a GABAergic neuron; through this collateral circuit the PC/RSC neuron regulates its own firing. An NMDA antagonist
would abolish inhibition in this collateral circuit, thereby removing inhibitory restraint over the firing of the PC/RSC
neuron at the same time that the PC/RSC neuron is being hyperstimulated through two disinhibited excitatory path-
ways. Our evidence suggests that a sigma receptor also exerts modulatory influence in this circuit, probably through
an action thatalters the function ofthe muscarinic receptor.
release ofexcitatory transmitters, both acetyl-
choline (ACh) and Glu, in the cerebral cortex.
By direct injection ofagents into the brain,
coupled with microdialysis methods
(20,28-30), additional aspects ofthe circuitry
depicted in Figure 1 have been confirmed,
whereas otheraspects remain to bestudied.
AgeDependencyofNMDAAntagonist
Neurotoxicity
Our early studies pertaining to NMDA
antagonist neurotoxicity focused exclusively
on the adult central nervous system (CNS),
with the exception of one study (31) in
which we administered NMDA antagonists
(MK801 and PCP) to rats at various stages of
development (fetal, infancy, adolescence, and
adulthood) and we examined the brains 4 hr
later for evidence ofacute pathomorphologi-
cal changes in cerebrocortical neurons. We
found that very high doses ofthese NMDA
antagonists do not trigger acute changes in
cerebrocortical neurons of immature rats
(fetal, infant, and early adolescent).
Although it appeared from these age-
dependency data that NMDA antagonists
might be relatively innocuous for the devel-
oping CNS, we have now discovered that the
opposite is the case-these agents have the
potential to destroy large numbers of neu-
rons in the developing brain, but they do so
by a mechanism that is entirely different
from the mechanism that mediates the adult
neurotoxicity ofthese agents. The neurotoxic
reaction in the immature brain was not
detected in our early study (31) because we
examined the brains only at 4 hr after treat-
ment, which is an appropriate time interval
for the adult mechanism but is not sufficient
for the development of a pathological reac-
tion in the immature brain. The interval to
develop a pathological reaction in the imma-
ture brain is 16-24 hr. Thus, our finding
that the immature brain is not sensitive to
the adult mechanism remains valid, but there
is a different mechanism by which blockade
of NMDA receptors can do great damage to
the developing brain.
Distinguishing Excitotoxic
from Apoptotic Neuronal
Cell Death
In the early to mid 1990s many authors
began reporting that an excitotoxic stimulus
can trigger cell death by an apoptotic mecha-
nism, and began speculating that an apop-
totic mechanism mediates cell death in a
number of CNS neurodegenerative diseases.
Unfortunately, as we recently discussed in
detail (32), most ofthe research pertaining to
this issue is fundamentally flawed. Typically,
invalid tests (e.g., DNA fragmentation tests)
for diagnosing apoptosis were used, making it
unclear whether the cell death process being
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identified as apoptosis is truly apoptosis. To
explore this issue we performed a side-by-side
ultrastructural comparison of a prototypic
excitotoxic process (Glu-induced degenera-
tion of neurons in the infant rat hypothala-
mus) and a prototypic apoptotic process,
physiological cell death, the natural process
by which biologically redundant neurons are
deleted from the developing brain. In this
work (33), we demonstrated by electron
microscopy that the type and sequence of
changes characterizing excitotoxic cell death
are entirely different from those characteriz-
ing apoptotic cell death. However, DNA
fragmentation tests (TUNEL stain or gel elec-
trophoresis) did not distinguish between the
two processes. These tests were positive for
both excitotoxic and apoptotic cell death, sig-
nifying that both types ofcell death degrade
DNA into similar fragments that are detected
by these methods, but because the two cell
death processes are clearly dissimilar by ultra-
structural analysis, one must conclude that
DNA fragmentation analysis is not a valid or
reliable test for diagnosing apoptosis. Our
finding that DNA fragmentation tests are not
specific for apoptosis and do not reliably dis-
tinguish apoptosis from excitotoxic cell death
is consistent with similar findings from sev-
eral other laboratories (34-36), including a
study from the Kerr laboratory (37) [Kerr
originally coined the term "apoptosis"(38)].
The Potential of NMDA
Antagonists to Induce
Apoptotic Neurodegeneration
in the Developing Brain
We began additional studies aimed at deter-
mining whether other examples of excito-
toxic neurodegeneration in the in vivo
mammalian brain could be distinguished
from apoptosis. The first example studied
was a new model that we developed for
investigating concussive head trauma in
infant rats. Using this model, we found that
a concussive force applied to the skull overly-
ing the parietal cortex of the 7-day-old rat
caused a relatively small excitotoxic lesion at
the impact site that evolved rapidly to end-
stage neuronal necrosis within 4 hr after
impact. Administration of MK801 before
concussive injury protected against this acute
excitotoxic lesion at the impact site (39). We
then discovered that over the ensuing 24 hr,
additional foci of neurodegeneration devel-
oped at distant sites and the degenerating
neurons at these sites qualified for a diagnosis
of apoptosis by ultrastructural criteria (40).
We applied various neuroprotective strategies
and were surprised to find that MK801 not
only failed to protect against the delayed, dis-
tant, apoptotic response, it increased the
magnitude ofthis response (41).
These findings raised an interesting
question: because NMDA antagonists pro-
mote the apoptotic neurodegenerative process
induced in the immature brain by head
trauma, is it possible that they might also
promote the spontaneous apoptotic neurode-
generative process that occurs naturally (inde-
pendent of head trauma) in the normal
developing brain? We investigated this and
found that indeed MK801, when adminis-
tered to 7-day-old infant rats, triggers a mas-
sive apoptotic neurodegenerative response
affecting many neurons in several major
regions ofthe developing brain (42). In addi-
tion, we administered PCP and ketamine to
7-day-old infant rats by dosing regimens cal-
culated to keep the rat pups intoxicated for up
to 8 hr and found that both ofthese NMDA
antagonists trigger a robust neurodegenerative
response in the developing brain (42).
In additional experiments, we determined
that the time window ofvulnerability to the
apoptosis-inducing action ofNMDA antago-
nists coincides with the period ofsynaptoge-
nesis, also known as the brain growth spurt
period. This period in the rat is largely con-
fined to the postnatal period; it begins 1 day
before birth and terminates at 10-14 days
after birth, whereas in the human it spans the
last 3 months ofpregnancy and extends into
the first several years postnatally (43). In
these experiments we also observed that
within the brain growth-spurt period, differ-
ent neuronal populations become sensitive at
different times to the mechanism by which
NMDA antagonists trigger apoptotic degen-
eration (42). Thus, depending on whether
exposure occurs in the early, mid, or late
stage of the brain growth-spurt period, dif-
ferent combinations of neuronal groups will
be deleted from the brain, from which it fol-
lows that this neurodevelopmental mecha-
nism has the potential to produce a variety of
neurobehavioral deficit syndromes.
The Potential of Ethanol and
GABAergic Agents to Induce
Apoptotic Neurodegeneration
in the Developing Brain
Evidence that ethanol has NMDA antagonist
properties (44-4) prompted us to evaluate its
ability to mimic the proapoptotic effects of
other NMDA antagonists. Administration of
ethanol to 7-day-old infant rats revealed that it
triggers a neurodegenerative response that is
even more robust than the response to MK801
(Figure 2) (48,49). Evaluation of the ethanol-
induced degenerative response by electron
microscopy revealed that it conforms to the
criteria for apoptotic cell death (Figure 3). The
window ofvulnerability to ethanol-induced
apoprosis was the same as that for MK8O1
(coincides with the synaptogenesis/brain
growth-spurt period). In addition, we found
that within the brain growth spurt period dif-
ferent neuronal populations become sensitive
at different times to the mechanism by which
ethanol triggers apoptotic degeneration. We
also determined that the minimum condition
for triggering neurodegeneration was main-
taining blood ethanol concentrations > 200
mg/dL for 4 consecutive hr, and that ifethanol
concentrations remained > 200 mg/dL for > 4
hr, the degenerative response became progres-
sively more severe and more widespread in
proportion to how long the concentrations
remained above this level.
Because ethanol triggered apoptosis in
some brain regions not typically affected by
NMDA antagonists, we attempted to iden-
tify other possible mechanisms to explain
ethanol's effects in these brain regions. We
were unable to demonstrate an appreciable
apoptotic response to agents that act as
either agonists or antagonists at dopamine
receptors; or that block kainic acid, mus-
carinic cholinergic receptors, or block volt-
age gated ion channels; but a robust
apoptotic response was triggered by agents
(benzodiazepines and barbiturates) that
mimic or potentiate the action of GABA at
GABAA receptors. We tested diazepam
(10-30 mg/kg ip at 0 hr, n = 6), clonazepam
(0.5-4 mg/kg at 0 hr, n = 6), pentobarbital
(10 mg/kg ip at 0 and 4 hr, n = 6), and phe-
nobarbital (50-75 mg/kg ip at 0 hr, n = 6).
These agents triggered widespread cell death
in the infant rat brain in a dose-dependent
manner; cell death, by ultrastructural analy-
sis, was apoptotic. The pattern of degenera-
tion was similar for each GABAergic agent
but this pattern differed in several major
respects from that induced by NMDA
antagonists (Figure 2). However, superim-
posinig one pattern on the other resulted in a
composite pattern closely resembling that
induced by ethanol (Figure 2).
Neurotoxicversus Neuroprotective
Effects ofEthanol in the Immature
versusAdult Brain
Evidence that ethanol has neurotoxic effects
on the immature brain that appear to be
mediated in part by the NMDA antagonist
properties ofethanol, and the knowledge that
NMDA antagonists also have neurotoxic
effects in the adult brain raises the interesting
question whether ethanol produces the
NMDA antagonist type of neurotoxicity in
the adult brain. To evaluate this we adminis-
tered large doses of ethanol to adult rats and
found no evidence for the neurotoxic reaction
that NMDA antagonists cause in the adult
cerebral cortex. We reasoned that failure of
ethanol to trigger a neurotoxic reaction might
imply that ethanol's potential to produce
neurotoxicity by blocking NMDA receptors
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is counteracted by some other property of
ethanol such as its action as a positive modu-
lator ofGABAA receptors. If this were the
case, and ifits action at GABA receptors were
particularly strong, it might be possible to
show that ethanol, in addition to being able
to protect against its own NMDA antagonist
neurotoxic potential, can protect against the
neurotoxic potential ofother NMDA antago-
nists. To test this we administered ethanol
together with a neurotoxic dose ofMK801
and found that ethanol in the adult brain
provides strong protection against the neuro-
toxic action ofMK801 (50).
Figure 2. (A-D) Low magnification (17.5x) light microscopic overviews of silver-stained transverse sections from the
parietal and cingulate cortex of8-day-old rats treated 24 hr previously with saline, MK-801 (NMDAantagonist), phe-
nobarbital, or ethanol. Abbreviations: AD, anterodorsal; AM, anteromedial; AV, anteroventral; LD, laterodorsal.
Degenerating neurons (small dark dots) are abundantly present in several brain regions after MK-801, phenobarbital,
or ethanol treatment but are onlysparsely present after saline treatment. MK-801 and phenobarbital both affect neu-
rons superficial to the cortical surface, whereas the middle cortical layers are affected prominently by phenobarbital
and are relatively spared by MK-801. The ethanol pattern resembles a combination ofthe MK-801 and phenobarbital
patterns. (E-H) Light micrographs (38.5x) depicting the anterior thalamus at the level of the LD, AD, AV, and AM
nuclei. MK-801 affects the LD, AV, and AM nuclei but not the AD nucleus, and phenobarbital prominently affects the
LD and AD butalmost entirely spares the AVand AM nuclei. The ethanol pattern includes all fournuclei, as would be
expected if it acts by a combined action involving the blockade of NMDA receptors plus the activation of GABAA
receptors. Adapted from lkonomidou etal. (49.
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Figure 3. Electron micrographs (1,350x) illustrating that apoptotic neurodegeneration induced by MK801, phenobar-
bital, or ethanol has the same ultrastructural appearance as physiological cell death, the natural cell death process
sparsely present in saline controls. As we recently described (31,40), in both spontaneous and induced apoptosis the
earliest signs are the formation of spherical chromatin masses and flocculent densities in the nucleus while the
nuclear envelope remains intact and cytoplasmic organelles are relatively unaltered. This is followed in the mid and
late stages by fragmentation of the nuclear envelope, intermixing of nucleoplasmic and cytoplasmic contents, and
progressive condensation of the entire cell. All four examples have a similar appearance because they are all in the
mid stage of apoptotic neurodegeneration. Adapted from lkonomidou etal. (49.
NMDAAntagonist
Properties of Nitrous Oxide
(Laughing Gas)
Nitrous oxide (laughing gas) is a general
anesthetic agent that has been used in den-
tistry and medicine for over a century, during
which time little insight into its mechanism
ofaction has been gained. Recently, we dis-
covered that nitrous oxide, in clinically rele-
vant concentrations, has all ofthe properties
of an NMDA antagonist. It protects neurons
in the rat hypothalamus against the excito-
toxic action ofsystemically administered
NMDA, it mimics PCP and MK801 in
injuring or killing neurons in the adult rat
cerebral cortex, and in patch clamp electro-
physiological experiments it blocks currents
induced in hippocampal neurons by NMDA.
In addition, its pharmacological profile as a
human anesthetic agent parallels that ofketa-
mine, a well known NMDA antagonist.
These findings were published recently (51),
as was afollow-up studydetailing the electro-
physiological profile ofnitrous oxide as an
NMDAantagonist (52.X
Significance ofThese
Findings in an Environmental
Health Context
In part, the public health significance of our
findings stems from the fact that ethanol is,
and has been for several thousand years, the
most widely abused drug in the world. Over
the millennia, ethanol has caused, and con-
tinues to cause, more neurodevelopmental
morbidity in human offspring than any other
agent in the human environment. Cases of
severe impairment (the tip ofthe iceberg) are
referred to as fetal alcohol syndrome (FAS)
and less severe impairment (the iceberg itself)
as fetal alcohol effects (FAE). The human
synaptogenesis/brain growth-spurt period
includes the last 3 months of gestation (43)
and the blood ethanol levels required to trig-
ger apoptotic neurodegeneration in the
immature rat brain (200 mg/dL lasting 2 4
hr) are in the range that a third-trimester
human fetus might be exposed to by a preg-
nant mother who imbibes ethanolic bever-
ages for several hours in a single drinking
episode. Our finding that transient exposure
ofthe in vivo mammalian brain to ethanol
during the synaptogenesis period causes neu-
rons to commit suicide by the tens ofmil-
lions provides a likely explanation for the
reduced brain mass and neurobehavioral dis-
turbances associated with the human
FAE/FAS. What types of neurobehavioral
disturbances might be expected from this
mechanism? Hyperactivity/attention deficit
disorder and learning disability ranging in
severity from mild impairment to mental
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retardation are the types of FAE/FAS
disturbance that have received the most
attention. However, Famy et al. (53) recently
studied a sizeable cohort of adult subjects
who received a FAE/FAS diagnosis in child-
hood and found that a high percentage
(72%) required psychiatric attention as
adults for a variety ofadult-onset psychiatric
problems, including a 40% incidence ofpsy-
chosis and 44% incidence ofmajor depres-
sive disorder. Thus, ethanol is a prime
example ofan environmental agent that can
quietly delete large numbers ofneurons from
the developing brain by an important mecha-
nism that we are just beginning to under-
stand. During a critical stage in development
(brain growth-spurt/synaptogenesis period)
when neurons are rapidly expanding their
dendritic trees and establishing trillions of
synaptic connections every day, ethanol
interferes with transmitter activity at two of
the most ubiquitous transmitter receptor sys-
tems in the developing brain-the NMDA
Glu and GABAA receptor systems. As a result
of this interference, developing neurons
apparently receive a message that develop-
mental events are not progressing normally,
which is interpreted as asignal to commit sui-
cide. Ofconsiderable interest is our finding
that within the brain growth-spurt period dif-
ferent neuronal populations have different
temporal patterns for responding to the
apoptosis-inducing effects ofethanol. Thus,
depending on the timing ofexposure, differ-
ent combinations ofneuronal groups will be
deleted, which explains why fetal ethanol
exposure gives rise to awide spectrum ofneu-
ropsychiatric disturbances (53). In other
recent writings (54) we discussed in greater
detail the possibility that certain patterns of
neuronal or receptor losses might be more
conducive to the subsequent development of
a psychotic illness such as schizophrenia,
whereas other patterns might be more con-
ducive to nonpsychotic psychiatric illnesses.
Because ethanol is both an NMDA antag-
onist and potentiator of GABAA transmis-
sion, it would be expected to have a
compound neurotoxic action in the develop-
ing brain (mediated simultaneously through
both NMDA and GABAA receptors).
However, in the adult brain ethanol may be
much less toxic because the neurotoxic poten-
tial of its NMDA receptor-blocking activity
will be counteracted and cancelled out by its
GABAA-potentiating activity. Our evidence
that ethanol triggers severe apoptotic neu-
rodegeneration in the developing brain (49),
but is relatively nontoxic or even neuropro-
tective in the adult brain (50), supports this
interpretation. Our evidence is also consistent
with the historical reality that over the mil-
lennia ethanol has served as the inebriant and
euphoriant of choice for human adults who
assumed that its effects are totally reversible
and harmless, an assumption that has resulted
in countless human fetuses being born with
myriad neurobehavioral disturbances ranging
from hyperactivity/attention-deficit and learn-
ing disorders to major adult-onset disturbances
including depression and psychosis (53).
To fully appreciate the public health
significance ofour findings, it must be recog-
nized that in addition to risk pertaining to
ethanol, both NMDA antagonists and
GABAA potentiators are drugs ofabuse and
also are drugs used frequently as sedatives,
tranquilizers, anticonvulsants, or anesthetics
in pediatric and/or obstetrical medicine.
Because the human brain growth spurt spans
not only the last trimester ofpregnancy but
several years after birth (41), the developing
human brain may be exposed to these agents
illicitly by drug-abusing pregnant mothers or
licitly by the medical profession. For example,
both ketamine and nitrous oxide are used fre-
quently in pediatric anesthesia and are com-
monly administered as an anesthetic cocktail
together with various agents (barbiturates,
benzodiazepines, isoflurane, and propofol)
that act as positive modulators of GABAA
receptors. Thus, studies are needed to clarify
whether exposure of the immature brain to
cocktails containing combinations ofNMDA
antagonists and GABAA potentiators during
the last halfofthe brain growth-spurt period
poses a risk ofsilently deleting large numbers
ofneurons from the developing brain.
Summary
In this paper we have summarized recent find-
ings pertaining to several environmental
agents (ethanol, phencyclidine, ketamine,
nitrous oxide, barbiturates, benzodiazepines,
halothane, isoflurane, and propofol) that have
the potential to delete large numbers of neu-
rons from the developing brain by a newly
discovered mechanism involving interference
in the action ofneurotransmitters (Glu and
GABA) at NMDAand GABAA receptors dur-
ing the synaptogenesis period, also known as
the brain growth-spurt period. Interference in
the activity ofthese transmitters during the
synaptogenesis period (the last trimester of
pregnancyand the first several years after birth
in humans) causes developing neurons to
commit suicide (die by apoptosis). Many of
these agents are drugs ofabuse to which the
human fetal brain may be exposed during the
third trimester by drug-abusing mothers.
Ethanol, the most widely abused drug in the
world, triggers massive apoptotic neurodegen-
eration in the developing brain by interfering
with both the NMDA and GABAA receptor
systems. This is a likely explanation for the
reduced brain mass and lifelong neurobehav-
ioral disturbances resulting from intrauterine
exposure ofthe human fetus to ethanol (FAS).
Exposure ofthe immature brain in a medical
treatment context is also ofconcern because
many ofthese agents are drugs used frequently
as sedatives, tranquilizers, anticonvulsants, or
anesthetics in pediatric and/or obstetrical
medicine. Because this is a newly discovered
mechanism, further research will be required
to develop a full appreciation for the nature
and degree ofrisk posed by exposure ofthe
developing human brain to environmental
agents that act bythis mechanism.
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